BioSpace News Archive

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) presented new analyses from LIVMARLI™ (maralixibat) oral solution clinical studies during the North American Society for Pediatric Gastroenterology Hepatology and Nutrition Annual Meeting, taking place virtually December 12-18, 2021.

Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), , today announced that it presented additional data from its ongoing Phase 2 clinical trial of KER-050 in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (“MDS”).

Annexon, Inc. (Nasdaq: ANNX), announced safety and dose-response data from its Phase 1 clinical trial of ANX009, the company’s subcutaneously administered product candidate that is designed to block the activity of C1q and the entire classical complement pathway.

While one in four blood cancer patients do not produce detectable antibodies after their first two doses of the COVID-19 vaccine, 43% of them will produce antibodies after a third dose, according to new data from The Leukemia & Lymphoma Society (LLS).

The Global FemTech Market valued at ~$22 billion (2020) is set to witness healthy growth rate of 15% in the next 5 years.

Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), today announced updated positive data from the Phase 1 dose escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with mutant nucleophosmin (mNPM1) or mixed lineage leukemia rearranged (MLLr) relapsed/refractory (R/R) acute leukemias.

Kite, a Gilead Company (Nasdaq: GILD), today announced primary results from ZUMA-12, a global, multicenter, single-arm, open-label Phase 2 study evaluating Yescarta® (axicabtagene ciloleucel) as part of first-line treatment in patients with high-risk large B-cell lymphoma (LBCL).

The board of directors of Eli Lilly and Company has announced a 15 percent increase in its quarterly dividend and declared a dividend for the first quarter of 2022 of $0.98 per share on outstanding common stock.

ERYTECH Pharma (Nasdaq & Euronext: ERYP),today announced a summary of its poster presentation at the 2021 ASH Annual Meeting evaluating GRASPA® (eryaspase) in acute lymphoblastic leukemia (ALL) as well as the acceptance of two abstracts evaluating eryaspase in advanced pancreatic cancer at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

Sensei Biotherapeutics, Inc., an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, announced it was added to the NASDAQ Biotechnology Index, effective prior to market open on Monday, December 20, 2021.